Frontlight ResearchEarly access
Active, not recruitingPhase 1
Phase 1 Study of GC1130A in Patients With Sanfilippo Syndrome Type A (MPS IIIA)
Key facts
- Who runs it
- GC Biopharma Corp
- Where
- Minneapolis and Oakland, United StatesSee the 2 sitesAlso in 1 other country, 2 sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 1
- People taking part
- 9 people, planned
- Started
- 21 Nov 2024
- Expected to end
- Jun 2027
- Type of study
- Interventional, 3 groups
- Treatments tested
- GC1130A
- Record updated
- 8 September 2026
Who can take part
- Age
- 12 months to 18 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Participants with documented MPS IIIA diagnosis
- Participants aged ≥ 12 months and ≤ 18 years
Who cannot take part
- Participants with previous complication from intraventricular drug administration
- Participants that received treatment with any investigational drug or a device intended as a treatment for MPS IIIA within 30 days or 5 half-lives prior to the study
- Participants that received a hematopoietic stem cell or bone marrow transplant or received gene therapy
- Participants with significant non-MPS IIIA related central nervous system impairment
- Participants with contraindications for MRI scans and for neurosurgery
Where in United States
Also in 1 other country, 2 sites
- University of MinnesotaMinneapolis, United States
- UCSF Benioff Children s HospitalOakland, United States
About the trial
What the trial wants to find out
The purpose of this study is to evaluate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of recombinant human heparan N-sulfatase (rhHNS, GC1130A) administered via intracerebroventricular access device in patients with Sanfilippo Syndrome Type A (MPS IIIA).
The 3 groups in the trial
- Cohort 1Treatment being tested
Treatment: GC1130A
- Cohort 2Treatment being tested
Treatment: GC1130A
- Cohort 3Treatment being tested
Treatment: GC1130A
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 1, Open-label, Ascending Dose Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of Recombinant Human Heparan N-Sulfatase (rhHNS, GC1130A) Via Intracerebroventricular Access Device in Patients With Sanfilippo Syndrome Type A (MPS IIIA)
- Record updated
- 8 September 2026